Breaking News Headlines Today | Ground News

Holiday Sale — Get 40% off Vantage for yourself or as a gift

biopharmadive.com image

News from biopharmadive.com

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and AllSides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

Moderna receives $54.3M investment for bird flu vaccine, covering axed federal mRNA contracts — REUTERS / pwu404

Moderna · United States

Moderna receives $54.3M investment for bird flu vaccine, covering axed federal mRNA contracts

100% Center coverage: 15 sources

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the funding that was cut off when the federal government canceled hundreds of millions of dollars in contracts. See the Story

Trump Announces Lower Drug Price Deals With 9 Pharmaceutical Companies

Donald Trump · United States

Trump Announces Lower Drug Price Deals With 9 Pharmaceutical Companies

55% Center coverage: 11 sources

(MedPage Today) -- President Trump announced on Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Pharmaceutical companies Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences...See the Story

New Drug Approved for Hypertrophic Cardiomyopathy

United States · United States

New Drug Approved for Hypertrophic Cardiomyopathy

100% Center coverage: 2 sources

(MedPage Today) -- The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced. Aficamten is an allosteric and reversible inhibitor of cardiac myosin motor activity...See the Story

Breaking News Topics Related to biopharmadive.com